Effect of Jinshui Xiangsheng Prescription on Clinical Outcome of Advanced Prostate Cancer Based on Propensity Score Matching

Xudong ZHU; Ming YANG; Hesong YE; Qi HE; Yiqun SHAO

doi:10.13422/j.cnki.syfjx.20221796

您当前的位置：

首页 >

文章列表页 >

Effect of Jinshui Xiangsheng Prescription on Clinical Outcome of Advanced Prostate Cancer Based on Propensity Score Matching

更新时间：2022-08-05

- Effect of Jinshui Xiangsheng Prescription on Clinical Outcome of Advanced Prostate Cancer Based on Propensity Score Matching
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 28, Issue 17, Pages: 84-90(2022)
- 作者机构：
  
  1.南京中医药大学第二附属医院，南京 210017
  2.上海中医药大学附属岳阳中西医结合医院，上海 200437
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20221796
  CLC： R22;R242;R287;R737.25
- Received：09 February 2022，
  
  Published Online：16 May 2022，
  
  Published：05 September 2022
- 稿件说明：
移动端阅览
朱旭东,杨明,叶和松等.基于倾向性评分法探讨金水相生方对晚期前列腺癌临床结局的影响[J].中国实验方剂学杂志,2022,28(17):84-90.

ZHU Xudong,YANG Ming,YE Hesong,et al.Effect of Jinshui Xiangsheng Prescription on Clinical Outcome of Advanced Prostate Cancer Based on Propensity Score Matching[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(17):84-90.
朱旭东,杨明,叶和松等.基于倾向性评分法探讨金水相生方对晚期前列腺癌临床结局的影响[J].中国实验方剂学杂志,2022,28(17):84-90. DOI： 10.13422/j.cnki.syfjx.20221796.

ZHU Xudong,YANG Ming,YE Hesong,et al.Effect of Jinshui Xiangsheng Prescription on Clinical Outcome of Advanced Prostate Cancer Based on Propensity Score Matching[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(17):84-90. DOI： 10.13422/j.cnki.syfjx.20221796.

摘要

目的

探讨金水相生方对晚期前列腺癌患者5年生存率临床结局的影响及相关影响因素分析。

方法

采集2014年5月1日至2016年5月1日上海中医药大学附属岳阳中西医结合医院和江苏省第二中医院泌尿外科门诊和病房收治的符合晚期前列腺癌并使用金水相生方辅助治疗的患者（观察组，155例），并根据患者年龄及Gleason评分同期采用倾向性评分法按1∶1的比例匹配未使用金水相生方的患者（对照组，155例）。观察各组患者1、3、5年雄激素抵抗率、生存率和中位生存期及中位无进展生存期，并通过卡方检验、

检验、Kaplan-Meier和Cox生存分析，分析筛选晚期前列腺癌预后因素。

结果

观察组1、3、5年雄激素抵抗率分别为9.0%（14/155）、72.3%（112/155）、92.9%（144/155），对照组1、3、5年雄激素抵抗率分别为20.6%（32/155）、87.7%（136/155）、97.4%（151/155），观察组1年（

=8.271，

0.01）、3年（

=11.613，

0.01）雄激素抵抗率显著低于对照组；观察组中位生存期和中位无进展生存期分别为（26.35±9.01）个月和（11.02±4.40）个月，对照组中位生存期和中位无进展生存期分别为（22.31±9.21）个月和（9.87±5.12）个月，与对照组比较，观察组中位生存期和中位无进展生存期显著延长，差异均具有统计学意义（

0.05，

0.01）；观察组1、3、5年累计生存率分别为96.1%（149/155）、80.6%（125/155）、39.4%（61/155）；对照组1、3、5年累计生存率分别为94.2%（146/155）、60.0%（93/155）、22.6%（35/155），观察组3年（

=15.828，

0.01）、5年（

=10.201，

0.01）累计生存率显著高于对照组。单因素分析结果显示，Gleason评分、初始前列腺特异性抗原（PSA）、肿瘤发生部位、肿瘤分期、去势方案、放疗、化疗、全雄阻断治疗、金水相生方为预后相关因素（

0.05，

0.01）；多因素分析结果显示，初始PSA、肿瘤部位、肿瘤分期为影响晚期前列腺癌患者生存时间的独立危险因素，而金水相生方、去势方案、化疗、放疗与全雄阻断是影响晚期前列腺癌预后的独立保护因素。

结论

金水相生方对晚期前列腺癌患者的生存有保护作用，可降低晚期前列腺癌雄激素抵抗率和死亡风险，使患者生存获益，值得进一步推广。

Abstract

Objective

To explore the effect of Jinshui Xiangsheng prescription on the five-year clinical survival outcome of patients with advanced prostate cancer.

Method

From May 1

2014 to May 1

2016

patients with advanced prostate cancer from Yueyang Hospital of Integrated Traditional Chinese and Western Medicine

Shanghai University of Traditional Chinese Medicine and the Urology Department of the Second Affiliated Hospital of Nanjing University of Chinese Medicine were collected and treated with Jinshui Xiangsheng prescription (155 cases in the observation group). According to age and Gleason score

the patients without Jinshui Xiangsheng prescription were matched in a ratio of 1∶1 (155 cases in the control group). The androgen resistance rate

survival rate

median survival time

and median progress free survival time in 1

5 years were observed. The prognostic factors of advanced prostate cancer were analyzed and screened out by Chi-square test

test

Kaplan-Meier and Cox survival analysis.

Result

The androgen resistance rates in the observation group in 1， 3， 5 years were 9.0% （14/155）， 72.3% （112/155）， and 92.9% （144/155）， respectively， and those in the control group were 20.6% （32/155）， 87.7% （136/155）， and 97.4% （151/155）. The 1-year （

=8.271，

0.01）and 3-year （

=11.613，

0.01） androgen resistance rates in the observation group were significantly lower than those in the control group. The median survival time and median progress free survival time in the observation group were （26.35±9.01） months and （11.02±4.40） months， respectively， and in the control group were （22.31±9.21） months and （9.87±5.12） months， respectively. The median survival time and median progress free survival time in the observation group were significantly longer than those in the control group （

0.05，

0.01）. The cumulative survival rates in 1， 3， 5 years in the observation group were 96.1% （149/155）， 80.6% （125/155）， and 39.4% （61/155）， respectively， and those in the control group were 94.2% （146/155）， 60.0% （93/155）， and 22.6% （35/155）， respectively. The 3-year （

=15.828，

0.01） and 5-year （

=10.201，

0.01） cumulative survival rates in the observation group were significantly higher than those in the control group. The monofactor analysis showed that the prognostic factors involved in Gleason score， initial prostate specific antigen （PSA）， tumor location， tumor stage， castration regimen， radiotherapy， chemotherapy， complete androgen blockade （CAB）， and Jinshui Xiangsheng prescription （

0.05，

0.01）. The multivariate analysis showed that initial PSA， tumor location， and tumor stage were the risk factors affecting the survival time of patients with advanced prostate cancer， whereas Jinshui Xiangsheng prescription， castration regimen， chemotherapy， radiotherapy， and CAB were the independent protective factors affecting the prognosis of advanced prostate cancer.

Conclusion

Jinshui Xiangsheng prescription has a protective effect on the survival of patients with advanced prostate cancer， which reduces the androgen resistance rate and death risk of advanced prostate cancer， thus benefiting the survival of patients. Therefore， it deserves further promotion.

关键词

Keywords

references

FLETCHER C E ， SULPICE E ， COMBE S ， et al . Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer ［J］. Oncogene ， 2019 ， 38 （ 28 ）： 5700 - 5724 .

STUOPELYTE K ， BAKAVICIUS A ， SABALIAUSKAITE R ， et al . Predicting abiraterone acetate treatment resistance from blood-circulating androgen receptor variants in castration-resistant prostate cancer ［J］. Eur Urol Suppl ， 2019 ， doi： 10.1016/S1569-9056（19）32143-8 http://dx.doi.org/10.1016/S1569-9056（19）32143-8 .

那彦群，叶章群，孙颖浩，等 . 中国泌尿外科疾病诊断治疗指南手册： 2014版［M］. 北京：科学出版社， 2014 ： 94 .

周宜强 . 实用中医肿瘤学［M］. 北京：中医古籍出版社， 2006 ， 422 - 424 .

RAWLA P . Epidemiology of prostate cancer ［J］. World J Oncol ， 2019 ， 10 （ 2 ）： 63 - 89 .

HA CHUNG B ， HORIE S ， CHIONG E . The incidence，mortality，and risk factors of prostate cancer in Asian men ［J］. Prostate Int ， 2019 ， 7 （ 1 ）： 1 - 8 .

王烨菁，傅忠星，王珏，等 . 2004~2011年上海市卢湾区社区人群前列腺癌发病与死亡分析［J］. 中国肿瘤， 2017 ， 26 （ 6 ）： 438 - 441 .

VAN HEMELRIJCK M ， FELLER A ， GARMO H ， et al . 946：Incidence of second malignancies for prostate cancer in the canton of Zurich，1980-2010 ［J］. Eur J Cancer ， 2014 ， doi： 10.1016/S0959-8049（14）50838-6 http://dx.doi.org/10.1016/S0959-8049（14）50838-6 .

MOTOSKO C C ， ZAKHEM G A ， POMERANZ M K ， et al . Acne：A side-effect of masculinizing hormonal therapy in transgender patients ［J］. Br J Dermatol ， 2019 ， 180 （ 1 ）： 26 - 30 .

CHOO S B ， SAIFULBAHRI A ， ZULLKIFLI S N ， et al . Adjuvant endocrine therapy side-effects among postmenopausal breast cancer patients in Malaysia ［J］. Climacteric ， 2019 ， 22 （ 2 ）： 175 - 181 .

BOURMAUD A ， ROUSSET V ， REGNIER-DENOIS V ， et al . Improving adherence to adjuvant endocrine therapy in breast cancer through a therapeutic educational approach：A feasibility study ［J］. Oncol Nurs Forum ， 2016 ， 43 （ 3 ）： E94 - E103 .

BUTLER M G ， MATTHEWS N A ， PATEL N ， et al . Impact of genetic subtypes of Prader-Willi syndrome with growth hormone therapy on intelligence and body mass index ［J］. Am J Med Genet A ， 2019 ， 179 （ 9 ）： 1826 - 1835 .

傅伟，王树声，李其信，等 . 扶正抑瘤方对前列腺癌内分泌治疗影响的Meta分析［J］. 中国中西医结合外科杂志， 2018 ， 24 （ 4 ）： 390 - 395 .

陈浩然，刘浩 . 从调理中医心-肝-肾轴论治前列腺癌去势综合征［J］. 世界中医药， 2021 ， 16 （ 21 ）： 3250 - 3255 .

邓仁芬，姚杨，李小江，等 . 贾英杰“守方微调”治疗前列腺癌经验［J］. 中医杂志， 2019 ， 60 （ 20 ）： 1724 - 1727 .

李波男，何清湖，周兴，等 . 谭新华治疗前列腺癌临床经验［J］. 中华中医药杂志， 2019 ， 34 （ 7 ）： 3074 - 3076 .

杨明，邵轶群，朱文静，等 . 彭培初分段论治晚期前列腺癌经验撷英［J］. 上海中医药杂志， 2016 ， 50 （ 7 ）： 1 - 4 .

余本坚，朱文静，王名杨，等 . 温肾法防治前列腺癌骨转移的研究进展［J］. 世界中医药， 2021 ， 16 （ 5 ）： 840 - 843 .

杨明，叶和松，王飞，等 . 金水相生法联合雄激素阻断治疗晚期前列腺癌 34例临床研究［J］. 江苏中医药， 2018 ， 50 （ 5 ）： 36 - 38 .

MAHON K L ， QU W ， LIN H M ， et al . Serum free methylated glutathione S-transferase 1 DNA levels，survival，and response to docetaxel in metastatic，castration-resistant prostate cancer：Post hoc analyses of data from a phase 3 trial ［J］. Eur Urol ， 2019 ， 76 （ 3 ）： 306 - 312 .

SHIOTA M ， NAKAMURA M ， YOKOMIZO A ， et al . Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer：a multi-institutional study ［J］. Cancer Chemother Pharmacol ， 2019 ， 84 （ 3 ）： 561 - 566 .

NAGPAL K ， FOOTE D ， TAN F ， et al . Development and validation of a deep learning algorithm for gleason grading of prostate cancer from biopsy specimens ［J］. JAMA Oncol ， 2020 ， 6 （ 9 ）： 1372 - 1380 .

谭信韬，刘秋礼，彭松，等 . 二甲双胍延缓前列腺癌进展的回顾性研究［J］. 第三军医大学学报， 2021 ， 43 （ 13 ）： 1253 - 1257 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

TCM Intervention in Prostate Cancer via Wnt/β-catenin Signaling Pathway： A Review

Expert Consensus on Traditional Chinese Medicine Diagnosis and Treatment of Complications After Androgen Deprivation Therapy for Prostate Cancer

Treatment of Prostate Cancer by Targeting PI3K/Akt Signaling Pathway with Traditional Chinese Medicine： A Review

Clinical Efficacy of Qingxin Zishen Decoction on Hot Flashes After Endocrine Therapy for Prostate Cancer and Its Preliminary Mechanism

Potential Mechanism of Houttuyniae Herba Against Prostate Cancer： A Review

Related Author

LIU Songjiang

ZHAO Junfei

XU Jingyu

LING Lu

Expert Consensus Writing Group of Urology Professional Committee of Chinese and Western Integrative Medicine，Chinese Medical Doctor Association

Expert Consensus Writing Group of Branch of Sexology of Traditional Chinese Medicine，China Sexology Association

LI Shenglong

TIAN Dacheng

Related Institution

The First Affiliated Hospital of Heilongjiang University of Chinese Medicine

The First Clinical Medical College of Heilongjiang University of Chinese Medicine

School of Basic Medicine， Gansu University of Chinese Medicine

Gansu Provincial Hospital of Traditional Chinese Medicine

Graduate School，Heilongjiang Academy of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰